Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Патологии системы комплемента

https://doi.org/10.24287/1726-1708-2020-19-1-131-138

Полный текст:

Аннотация

Система комплемента – часть иммунной системы, которая обеспечивает защиту организма от вторжения чужеродных патогенов. Различного рода нарушения этой системы могут способствовать развитию ряда тяжелых заболеваний. В данном обзоре описаны различные нарушения в работе системы комплемента, а также показано, к каким патологиям это может привести.

Об авторах

А. А. Бутылин
ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»
Россия
Москва


А. Е. Филиппова
ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН
Россия
Москва


С. С. Шахиджанов
ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН
Россия

научный сотрудник,

119991, Москва, ул. Косыгина, 4 



Ф. И. Атауллаханов
ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»; ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН; ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; ФГАОУ ВО «Московский физико-технический институт (государственный университет)»
Россия
Москва


Список литературы

1. МКБ 10, Международная Классификация Болезней, коды заболеваний, расшифровка диагнозов http://mkb-10v.ru/

2. Дефекты в системе комплемента коды МКБ 11. http://icd11.ru/defecty-v-system-komplementa/

3. Smith-Jackson K., Yang Y., Denton H., Pappworth I.Y., Cooke K., Barlow P.N., et al. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019 Mar 1; 129 (3): 1061–75.

4. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 2014 Oct; 61 (2): 110–7.

5. Lewis L.A., Ram S. Meningococcal disease and the complement system. Virulence 2014 Jan 1; 5 (1): 98–126.

6. Truedsson L. Classical pathway deficiencies - A short analytical review. Mol Immunol 2015 Nov; 68 (1): 14–9.

7. Pan L., Lu M.-P., Wang J.-H., Xu M., Yang S.-R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 2019 Feb 22.

8. Macedo A.C.L., Isaac L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol 2016; 7: 55.

9. Panelius J., Meri S. Complement system in dermatological diseases – fire under the skin. Front Med (Lausanne) 2015; 2: 3.

10. Lintner K.E., Wu Y.L., Yang Y., Spencer C.H., Hauptmann G., Hebert L.A., et al. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol 2016; 7: 36.

11. Liphaus B.L., Umetsu N., Jesus A.A., Bando S.Y., Silva C.A., Carneiro-Sampaio M. Molecular characterization of the complement C1q, C2 and C4 genes in Brazilian patients with juvenile systemic lupus erythematosus. Clinics (Sao Paulo) 2015 Mar; 70 (3): 220–7.

12. Degn S.E., Jensenius J.C., Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet 2011 Jun 10; 88 (6): 689–705.

13. Slade C., Bosco J., Unglik G., Bleasel K., Nagel M., Winship I. Deficiency in complement factor B. N Engl J Med 2013 Oct 24; 369 (17): 1667–9.

14. Ohsawa I., Honda D., Nagamachi S., Hisada A., Shimamoto M., Inoshita H., et al. Clinical and laboratory characteristics that differentiate hereditary angioedema in 72 patients with angioedema. Allergol Int 2014 Dec; 63 (4): 595–602.

15. RESERVED IU-AR. Orphanet: Search a disease [Internet]. [cited 2019 Mar 16]. Available from: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN

16. Botto M., Kirschfink M., Macor P., Pickering M.C., Würzner R., Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009 Sep; 46 (14): 2774–83.

17. Wong E.K.S., Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018; 40 (1): 49–64.

18. Morgan B.P., Harris C.L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015 Dec; 14 (12): 857–77.

19. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 Oct 4; 413 (6855): 488–94.

20. Dragon-Durey M.-A., Frémeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 2005 Nov; 27 (3): 359–74.

21. Funato M., Uemura O., Ushijima K., Ohnishi H., Orii K., Kato Z., et al. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome. J Clin Immunol 2014 Aug; 34 (6): 691–5.

22. Dickenmann M., Schifferli J.A. Atypical hemolytic uremic syndrome: update on the complement system and what is new. Nephron Clin Pract 2010; 114 (4): 219–35.

23. Noris M., Bresin E., Mele C., Remuzzi G. Genetic Atypical Hemolytic-Uremic Syndrome. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J., Mefford H.C., et al., editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1367/

24. Luzzatto L. PNH from mutations of another PIG gene. Blood 2013 Aug 15; 122 (7): 1099–100.

25. Yamashina M., Ueda E., Kinoshita T., Takami T., Ojima A., Ono H., et al. Inherited Complete Deficiency of 20-Kilodalton Homologous Restriction Factor (CD59) as a Cause of Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine 1990 Oct 25; 323 (17): 1184–9.

26. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993 May 21; 73 (4): 703–11.

27. de Latour R.P., Mary J.Y., Salanoubat C., Terriou L., Etienne G., Mohty M., et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008 Oct 15; 112 (8): 3099–106.

28. Dulau-Florea A., Maric I., Calvo K.R., Braylan R.C. Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates. Seminars in Hematology 2019 Jan 1; 56 (1): 65–8.

29. Merrill S.A., Brodsky R.A. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program 2018 30; 2018 (1): 371–6.

30. Wijnsma K.L., Ter Heine R., Moes D.J.A.R., Langemeijer S., Schols S.E.M., Volokhina E.B., et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019 Feb 13;

31. Maller J., George S., Purcell S., Fagerness J., Altshuler D., Daly M.J., et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006 Sep; 38 (9): 1055–9.

32. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005 Apr 15; 308 (5720): 421–4.

33. Rohrer B., Frazer-Abel A., Leonard A., Ratnapriya R., Ward T., Pietraszkiewicz A., et al. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. Mol Vis 2019 Feb 8; 25: 79–92.

34. Maller J.B., Fagerness J.A., Reynolds R.C., Neale B.M., Daly M.J., Seddon J.M. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007 Oct; 39 (10): 1200–1.

35. Landowski M., Kelly U., Klingeborn M., Groelle M., Ding J.-D., Grigsby D., et al. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. PNAS 2019 Feb 26; 116 (9): 3703–11.

36. Rhoades W., Dickson D., Do D.V. Potential role of lampalizumab for treatment of geographic atrophy. Clin Ophthalmol 2015; 9: 1049–56.

37. ClinicalTrials.gov. A study investigating the effcacy and safety of lampalizumab intravitreal injections in participants with geographic atrophy secondary to age-related macular degeneration (SPECTRI). Available from: https://clinicaltrials.gov/ct2/show/NCT02247531. NLM identifer: NCT02247531. Accessed July 28, 2017.

38. Frazer-Abel A., Sepiashvili L., Mbughuni M.M., Willrich M.А.V. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem2016; 77: 1–75.

39. Yuan X., Gavriilaki E., Thanassi J.A., Yang G., Baines A.C., Podos S.D., et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 2017; 102 (3): 466–75.

40. Schrezenmeier H., Höchsmann B. Drugs that inhibit complement. Transfus Apher Sci 2012 Feb; 46 (1): 87–92.


Для цитирования:


Бутылин А.А., Филиппова А.Е., Шахиджанов С.С., Атауллаханов Ф.И. Патологии системы комплемента. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(1):131-138. https://doi.org/10.24287/1726-1708-2020-19-1-131-138

For citation:


Butilin A.A., Filippova A.E., Shakhidzhanov S.S., Ataullakhanov F.I. Pathologies of the complement system. Pediatric Hematology/Oncology and Immunopathology. 2020;19(1):131-138. (In Russ.) https://doi.org/10.24287/1726-1708-2020-19-1-131-138

Просмотров: 92


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)